We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By closing this message, you are consenting to our use of cookies.

Hematology

Currently calling for submissions for the 2021 volume for the following article types: Original Research, Study Characteristics, Clinical Studies, Systematic Reviews, Reviews, Mini Reviews, Case Series, and Commentaries.

In the Hematology section, we consider for publication the latest advances in:

Anticoagulation

Heparin-induced thrombocytopenia

Aplastic anemia

Leukemia

Benign hematology

Lymphoma

Bleeding

Malignant hematology

Blood and marrow transplantation

Platelet aggregometry

Bone marrow failure

Platelet function defect

Cellular therapy

ROTEM

Chimeric antigen receptor T cell therapy

Sickle cell disease

Classical hematology

TEG

Cytopenia

Thalassemia

DOAC

Thrombocytopenia

ECMO

Thrombosis

Hematopoietic stem cell

VAD

Hemoglobinopathy

Viscoelastometry

 

Annals of Medicine

Q1 Impact Factor Best Quartile

Two-Year Impact Factor 4.709
Five-Year Impact Factor 4.554

CiteScore 7.2

PubMed Central® and MEDLINE® Indexed

Meet the Section Editors

Jun Teruya, MD, DSc, FCAP, Professor (tenured) in Dept. of Pathology & Immunology and Vice Chairman for Education; Professor (tenured) of Pediatrics and Medicine; Baylor College of Medicine, Houston, Texas; Chief of Division of Transfusion Medicine & Coagulation, Texas Children's Hospital, Houston, Texas, USA

Dr. Teruya is tenured Professor of Pathology & Immunology and Vice Chair for Education at Baylor College of Medicine. He is also Chief of Division of Transfusion Medicine & Coagulation at Texas Children’s Hospital. Teruya was an Internist and Hematologist for 10 years before he moved to the United States. He completed residency training in Clinical Pathology and fellowship training at Massachusetts General Hospital, Harvard Medical School in Boston. He has published more than 140 original articles and a number of book chapters including UpToDate. Teruya has been a Chair of Scientific Subcommittee of Plasma Coagulation Inhibitors of ISTH since 2017. Teruya's research interests are in ECMO (extracorporeal membrane oxygenation), VAD (ventricular assist device), hemostasis in liver failure, and thromboelastometry. He has received a number of teaching awards from medical students, residents, and fellows and has been selected as the Best Doctors in America® since 2013. He was also voted Funniest Professor Award, by medical students for his lectures on hemostasis. He successfully organized ECMO/VAD Interest Group for ISTH in 2017--The group consists of world experts of ECMO and/or VAD from USA, Canada, Germany, Netherlands, France, and Australia.

Bhagirathbhai Dholaria, M.B.B.S., Assistant Professor of Medicine, Dept. of Medicine, Division of Hematology/ Oncology, Vanderbilt University Medical Center, Nashville, TN, USA

Dr. Dholaria is currently an assistant professor in the Department of Hematology-Oncology at Vanderbilt University Medical Center, Nashville, TN. His areas of specialization and primary research focus are lymphoid neoplasms, plasma cell malignancies, adoptive cellular therapies and stem cell transplantation. He has conducted studies investigating the outcomes of non-Hodgkin lymphoma patients undergoing chimeric antigen receptor T-cell (CAR-T) therapies. He is involved in translational research investigating the biomarkers of CAR T-cell therapy-associated toxicities. He has also conducted several observational studies utilizing cancer registries to study transplant outcomes of acute leukemia patients and presented his findings in national meetings. His team’s work on stem cell transplantation has been published in multiple manuscripts. His current research efforts are focused on testing novel agents to mitigate cytokine release syndrome and neurotoxicity associated with CAR T-cell therapy.

Why is Annals of Medicine the best publication for your research?

Fully open access, general medical journal publishing articles under a CC BY license, allowing maximum sharing and reuse of articles to our international readership;

Publishing all scientifically valid research, including reporting of negative and null data, from translational to clinical research in all disciplines and therapy areas;

Led by an international editorial team of subject experts who ensure a constructive and rigorous peer review process;

Your research is promoted via a tailored, multi-channel approach to maximize visibility, readership and impact.

Recent Articles     Instructions for Authors     SUBMIT MANUSCRIPT

Editing Services

To help improve your manuscript and prepare it for submission, Taylor & Francis provides a range of editing services such as English Language Editing, which will ensure that your article is free of spelling and grammar errors, Translation, and Artwork Preparation.

Learn more